Orca Bio's manufacturing facility in Sacramento, California. Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to prevent graft-versus ...

Affirmative therapy, or LGBTQ+ affirmative therapy, is a therapeutic approach that validates and advocates for the needs of sexual and gender minority individuals. Affirmative therapy employs a ...

Add Yahoo as a preferred source to see more of our stories on Google. Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020.

June 30 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Orca Bio's therapy for the treatment of ‌certain blood cancers, which also aims to lower the risk of stem cell ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. David Meek bought Bluebird Bio last year ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Complexity is inherent to cell and gene therapy and that includes its manufacturing, where moving towards producing products at a commercial scale continues to challenge companies in the sector. To ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...

Many blood cancers can be treated with a potentially curative stem cell transplant, but this procedure introduces a serious complication risk that can become deadly. A new type of cell therapy gives ...

A new gene-editing company emerged from stealth on Tuesday with $230 million in committed financing, a reverse merger with a defunct oncology biotech, and a lead drug candidate licensed from a Chinese ...

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies The approval of TREGZI, clinically ...